Better Health for All

Adagene Inc. is a clinical-stage biopharmaceutical company entirely focused on discovering and developing novel antibody-based cancer immunotherapies, addressing unmet medical needs in oncology. Its pipeline, including ADG126, ADG116, ADG206, ADG153, and ADG106, is dedicated to creating innovative cancer treatments. All of the company's R&D expenses, which were US$36.6 million in 2023

and US$81.3 million in 2022, are directed towards health improvement and expanding its Dynamic Precision (DPL) platform. The company has no revenue from products with established negative health outcomes, with revenue primarily from technology licensing agreements. However, clinical trial data for ADG126 in combination with pembrolizumab showed Grade 3 treatment-related adverse events (TRAEs) in 5 out of 46 patients (10.8%), which translates to an adverse events rate of over 100,000 per million users. While no Grade 4 or 5 TRAEs were reported, and ADG126 is designed as a 'SAFEbody' to reduce toxicity, the quantitative threshold for adverse events is met.

Fair Money & Economic Opportunity

Adagene Inc. is a clinical-stage biopharmaceutical company. The provided articles discuss corporate governance

and a strategic investment , including a US$25 million investment by Sanofi and US$85.2 million in cash and cash equivalents as of December 31, 2024, expected to fund operations into 2027 . As the company's core business is not in financial services, lending, or deposit services, there is no information or data in the articles related to financial inclusion, fair lending practices, or economic opportunity for consumers. Therefore, all metrics pertaining to fair money and economic opportunity are not applicable based on the available evidence.

Fair Pay & Worker Respect

The company has an average employee rating of 3.6 out of 5 (72%) on Glassdoor, based on 6 reviews

. Specific ratings include 4.3 for culture, 4.7 for diversity, 3.4 for work-life balance, 3.6 for senior management, 3.7 for compensation, and 4.2 for career opportunity . There are no reported regulatory actions, violations, or fines .

Fair Trade & Ethical Sourcing

No information relevant to Fair Trade & Ethical Sourcing for Adagene Inc. was found in the provided articles.

The articles either focused on the company's biopharmaceutical business without addressing supply chain practices or were inaccessible/irrelevant to the requested metrics .

Honest & Fair Business

No data relevant to the 'Honest & Fair Business' ethical value or the requested key performance indicators was found in the provided articles for ADAG.US. The articles consist of biographical information for a board member

, a list of corporate governance committee members and their roles , and a list of SEC filings , none of which contain specific details on regulatory fines, transparency benchmarks, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board conflicts of interest, anti-corruption policies, or third-party verification of ethical claims.

Kind to Animals

No explicit animal testing policy is mentioned.

The company relies on "robust translational studies" in animals that better reflect how drug candidates will work in humans.

Planet-Friendly Business

Adagene Inc. reported water usage of 82,500 gallons (312.2 m³) in 2023.

With net revenue of $17.3 million for the first six months of 2023, this translates to approximately 9.02 m³ per $1 million in revenue. The company conducted 18 environmental impact assessments in 2023. No environmental compliance violations were mentioned in the provided articles. For 2023, the company reported Scope 1 emissions of 672 metric tons CO2e and Scope 2 emissions of 1,845 metric tons CO2e, totaling 2,517 tCO2e. Scope 3 emissions were not provided. Adagene Inc. invested $425,000 in carbon offsets in 2023, but the quality of these offsets was not specified. The company reported net losses of $4.1 million for the first six months of 2023 and $33.4 million for 2024, making the percentage of EBIT reinvested in climate-positive initiatives incalculable. No information was provided regarding science-based carbon reduction targets, renewable energy usage, green building certifications, waste diversion rates, EU Sustainable Taxonomy alignment for capital expenditure, lifecycle environmental assessments for products, recycled to virgin material ratios, carbon offset quality rating, supply chain climate transparency, supplier SBTi targets, biodiversity efforts, deforestation policies, net-zero targets, TCFD alignment, climate scenario analysis, stranded asset transparency, percentage of water from stressed basins, packaging CO2 reduction, climate justice initiatives, just transition programs, or climate adaptation financing.

Respect for Cultures & Communities

Adagene Inc. is a clinical-stage biopharmaceutical company. Its reported formal partnerships are with other pharmaceutical companies, specifically Exelixis, Sanofi, and Roche

, for drug development and commercialization. There is no evidence of formal partnerships with indigenous or local community groups, which aligns with a business model where such partnerships are not applicable. No information is provided regarding any other KPIs related to respect for cultures and communities.

Safe & Smart Tech

Adagene Inc.'s privacy policy states that users have rights to access, rectify, and erase their data, consistent with GDPR requirements for EU users

. The company also mentions GDPR compliance for its operations involving EU users .

Zero Waste & Sustainable Products

Adagene Inc. has no reported waste disposal violations or fines.

The company does not have publicly available specific waste reduction targets.